ALK and non-small cell lung carcinoma: Although 2 recent phase III trials (Keynote 189 and IMPOWER 150) showed that standard chemotherapy plus a checkpoint inhibitor extended progression-free survival and overall survival compared with chemotherapy alone,[6,7] pemetrexed-based chemotherapy regimen remains as one of first-line treatments for patients with NSCLC who lack sensitizing EGFR mutations or ALK rearrangement.